Consistently, the variant containing the PEG linker (IFN-γ-PEG-PPB) generated the most remarkable antifibrotic activity: The compound blocked both angiogenesis and hepatic inflammation and even caused fibrolysis in the advanced stage of hepatic fibrosis, while it also led to a decline of IFN-γ-associated adverse reactions (Bansal et al., 2011). Here, IFNG is linked to Hepatic fibrosis.